| Ytd | 85.24% | |
| 1y | 260.40% |
| Open | 7.92 | Prev Close | 7.67 | Low | 7.22 | High | 7.95 | Mkt Cap | 126.57M |
| Vol | 132.06K | Avg Vol | 229.23K | EPS | -1.15 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.17 | Short Ratio | 0.31 | Inst. Own | 9.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 5.75 | 200-d Avg | 4.30 | 1yr Est | 0.00 |
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile,
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today a
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or t
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Comb
Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Dec
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today a
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.18) per share. This is a 37.93 pe
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.34) per share. This is a 25.93 pe
LIXTE Biotechnology Holdings (NASDAQ:LIXT) announced an expansion of its collaboration with The Univ
On December 30, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the "Company&#
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be present
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT) a biote
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 pe
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietar
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a clinical stage pharmaceu
https://ppubs.uspto.gov/api/pdf/downloadPdf/12343342?requestToken=eyJzdWIiOiIxMDU2YWQ0Yy05M2E5LTQyYT